Jim Cramer on Aquestive Therapeutics: “I Think It’s a Very Interesting Spec”

“We cognize the problem. Let’s not look astatine that. We look astatine the pipeline and we cognize that… I’m successful favour of investing successful a spec of immoderate institution involving tense system, okay? Any institution involving the encephalon and they’re there, and I deliberation it’s a precise absorbing spec.”

Photo by Joshua Mayo connected Unsplash

Aquestive Therapeutics, Inc. (NASDAQ:AQST) develops therapies for neurological, psychiatric, and allergy-related conditions. Its main products see Libervant, Suboxone, Sympazan, and Azstarys. Cramer advised a small caution erstwhile helium discussed the banal during the September 18 episode, arsenic helium commented:

“For the past fewer years, this banal has recovered caller life, climbing backmost to the mid azygous digits, mostly acknowledgment to the increasing excitement astir their EpiPen replacement that tin beryllium taken by rima for exigency allergy treatments… I deliberation radical are close to beryllium excited. If this cause tin beryllium approved, I deliberation it could beryllium huge. That’s right, huge… The existent question present is whether it inactive makes consciousness to bargain the banal astatine these levels. You request to recognize that this is simply a wholly binary situation. If Anaphylm gets FDA support successful the adjacent fewer months, Aquestive banal volition soar…

While we admit the imaginable of AQST arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the champion short-term AI stock.